Inhibition of ACLY overcomes cancer immunotherapy resistance via polyunsaturated fatty acids peroxidation and cGAS-STING activation
W Xiang, H Lv, F Xing, X Sun, Y Ma, L Wu, G Lv… - Science …, 2023 - science.org
Adenosine 5′-triphosphate citrate lyase (ACLY) is a cytosolic enzyme that converts citrate
into acetyl–coenzyme A for fatty acid and cholesterol biosynthesis. ACLY is up-regulated or …
into acetyl–coenzyme A for fatty acid and cholesterol biosynthesis. ACLY is up-regulated or …
Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation
F Müller, JKM Lim, CM Bebber, E Seidel… - Cell Death & …, 2023 - nature.com
Oncogenic KRAS is the key driver oncogene for several of the most aggressive human
cancers. One key feature of oncogenic KRAS expression is an early increase in cellular …
cancers. One key feature of oncogenic KRAS expression is an early increase in cellular …
[HTML][HTML] Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer
Tumor mutational burden and heterogeneity has been suggested to fuel resistance to many
targeted therapies. The cytosine deaminase APOBEC proteins have been implicated in the …
targeted therapies. The cytosine deaminase APOBEC proteins have been implicated in the …
The UBA1-STUB1 axis mediates cancer immune escape and resistance to checkpoint blockade
How cancer cells escape immune surveillance and resist immune checkpoint blockade
(ICB) remains to be fully elucidated. By screening candidate genes frequently gained in …
(ICB) remains to be fully elucidated. By screening candidate genes frequently gained in …
The emerging roles of sphingosine 1-phosphate and SphK1 in cancer resistance: a promising therapeutic target
Cancer chemoresistance is a problematic dilemma that significantly restrains numerous
cancer management protocols. It can promote cancer recurrence, spreading of cancer, and …
cancer management protocols. It can promote cancer recurrence, spreading of cancer, and …
NDRG1 in cancer: a suppressor, promoter, or both?
V Joshi, SR Lakhani, AE McCart Reed - Cancers, 2022 - mdpi.com
Simple Summary NDRG1 (N-myc downregulated gene-1) has been reported to suppress
metastasis, to be a biomarker of poor outcome, and to be a facilitator of disease progression …
metastasis, to be a biomarker of poor outcome, and to be a facilitator of disease progression …
Targeting conserved TIM3+VISTA+ tumor-associated macrophages overcomes resistance to cancer immunotherapy
Despite the success of immunotherapy, overcoming immunoresistance in cancer remains
challenging. We identified a unique niche of tumor-associated macrophages (TAMs) …
challenging. We identified a unique niche of tumor-associated macrophages (TAMs) …
Glucose transporter 1-mediated transcytosis of glucosamine-labeled liposomal ceramide targets hypoxia niches and cancer stem cells to enhance therapeutic efficacy
Tumour hypoxia plays an important role in modulating tumorigenesis, angiogenesis,
invasion, immunosuppression, resistance to treatment, and even maintenance of the …
invasion, immunosuppression, resistance to treatment, and even maintenance of the …
PD-L1-directed PlGF/VEGF blockade synergizes with chemotherapy by targeting CD141+ cancer-associated fibroblasts in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) has a poor 5-year overall survival rate. Patients
with PDAC display limited benefits after undergoing chemotherapy or immunotherapy …
with PDAC display limited benefits after undergoing chemotherapy or immunotherapy …
LncRNA LITATS1 suppresses TGF‐β‐induced EMT and cancer cell plasticity by potentiating TβRI degradation
Epithelial cells acquire mesenchymal phenotypes through epithelial‐mesenchymal
transition (EMT) during cancer progression. However, how epithelial cells retain their …
transition (EMT) during cancer progression. However, how epithelial cells retain their …